The Zhitong Finance App learned that Yongtai Bio-B (06978) rose more than 8%. As of press release, it had risen 8.41% to HK$3.61.
According to news, Yongtai Biotech and Corning signed a memorandum of business cooperation in Beijing on March 1. According to reports, with the signing of the Memorandum of Business Cooperation, the two sides will carry out deeper cooperation in the development and marketing of customized products, testing laboratories, new products, etc., to promote the commercialization and implementation of Yongtai's important R&D pipelines.
A previous research report by Societe Generale Securities pointed out that cellular immunotherapy has grown rapidly in recent years, showing great potential. The company has been deeply involved in the field of cellular immunotherapy for many years and has a highly integrated T-cell immunotherapy drug R&D platform and production base. Its pipeline is laid out in many segments, and the R&D progress of some products is also leading in China, so it is expected to enjoy the dividends of industry growth.